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Objectives.This studyattemptedto analyzeimmediateand
long-termangiographicaud clinical results of coronarystent
implantationforrestenosisin a consecutivegroupof patients.
Background,The rate of stent utilizationin patientswith
coronaryarterydisease has increasedexponentiallyin recent
years,Thereare manyunansweredquestionsaboutthe use of
stentingin patientswithrestenosis,particularlywithrespectto
lateclinicalandangiographicresults.
Methods.A totalof 159stentswereimplantedin 128consecu-
tivepatientswith 139lesions (mean1.3 stents/patient).A tech-
niqueof optimalstent expansionwas used in all patients,and
intravascularultrasoundguidancewithno subsequentanticoag-
ulationwasperformedin 41 patients.
Results.Stent implantationwas successfulin 126 patients
(98%).Four patients (3,1%)had complications(in two after
Restenosisafter percutaneoustransluminalcoronaryangio-
plasty(PTCA)of a coronarylesionhasbeenreportedto have
an incidencerate of 17% to 60% (l). The most common
approachto treatmentof a restenoticlesionafter PTCAhas
been a repeat balloondilationprocedure.This strategyis






reports concerningits use in treatingrestenoticlesionsare




The purposeof this studyis to analyzethe resultsof our
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successfulstenting):death in one, emergencybypass surgery
operationin twoand subacutestent thrombosisin one. Stents
wereimplantedwitha finalballoonsize (mean& SD) of 3.5 &
0.5mmanda meanmaximalpressureof 11 &4 atm(range8 to




survivalratewas98Y0at 1yearandat 3 years,andtheevent-free








underwentcoronarystentingat our institution.The study
cohort comprised128 consecutivepatientswho underwent
coronarystentingto treat a restenoticlesionafter successful
PTCA. All patients includedin this study had at least 12
monthsof clinicalfollow-up.
Stenting procedure.Patients were treated with aspirin,
325 mg daily,and calciumchannelblockingagents before
stenting.A bolusof 10,000U ofheparinwasgivenaftersheath
insertionand a repeatbolusof 5,000U wasgivento maintain




tion.The coronaryPalmaz-Schatzstent (Johnson& Johnson
InterventionalSystem),itsshortversionandthePalmazbiliary
stent were the stents most frequentlyimplanted.For most
proceduresthese stentswere hand-crimpedon a PTCAbal-
loon. They were rarely implantedwith a dedicated stent
deliverysystem.Occasionally,other stents were used: the
Gianturco-Roubin(CookInc.),Wiktor(MedtronicInc.),Mi-
cro (AdvancedVascularEngineering,Canada) and Cordis
(CordisCorp.) stents.Use of these stentswas restrictedto
anatomicsettingsnot consideredideal for the slotted tube
























wereimplantedto ensureminimaloverlapandno gaps.In the
earlyperiodof thisexperiencean oversizedballoonwasused
to perform the final dilation.Since 1993,stents have been









lyzedbypersonnelnot involvedin the stentingprocedureand
withoutknowledgeofthe IVUSresults.Thevesselsandlesions
were measuredby usingdigitalcalipers(Brownand Sharp)
froman opticallymagnifiedimagein a singlematched“worst”
view.The guidingcatheterwasusedas a referenceobjectfor
calibration.Minimallumen diameter (MLD) and percent
stenosiswere obtainedin the baseline,final and follow-up
angiograms.The meanreferencelumenwascalculatedas the
averageof the proximaland distalreferencelumens.Lesion
lengthwasmeasuredas the distancefromthe shouldersof the
lesion.Lesionswerecharacterizedaccordingto the American
Heart Association/AmericanCollegeof Cardiology(AH-W
ACC) classification.A long lesionwas definedas a single
continuousnarrowing>15 mmin length.
The followingvariableswere calculatedfrom the angio-
graphicanalysis:acutegain= MLDafterstentingminusMLD
before intervention;late loss = MLD after stentingminus
MLD at follow-up;relativegain = acute gain dividedby
reference vessel size; relative/oss = late loss dividedby
referencevesselsize;net gain index = (MLD at follow-up
minusMLDbeforestenting)dividedbyreferencevesselsize.
Angiographicfindingsuchas thrombus,calcifications,dis-
sections,side branch occlusionand vesselrupturewere re-
cordedand analyzed.
Medicationsafterstenting, In the firstperiodofthisstudy,
patientswere treated with standardpostproceduralheparin,
started3 or 4 h after sheathremovaland continueduntiloral
anticoagulationwithwarfarinresultedin prolongationof pro-
thrombintime to an internationalnormalizedratio of 2.0 to
3.5.Warfarintherapywascontinuedfor 1monthin association
withaspirin,325mg daily.In the mostrecentperiodof this
studyand sinceperformanceof stentimplantationwithIWS
guidanceand high pressure dilation,patients receivedno





stent implantationon the target lesionwith <3070residual
stenosisand with the patientleavingthe cardiaccatheteriza-
tionlaboratoryaliveandfreeof Q wavemyocardialinfarction
or emergencycoronaryarterybypasssurgery(CABG).Major
events= death, CABG, myocardialinfarction(Q wave or
non-Qwave),emergencyPTCA and vascularcomplications.
Death= anydeath irrespectiveof cause.Q wavemyocardial
infarction= presenceof a new pathologicQ wave in the
electrocardiogramin associationwithan elevationof cardiac
serumenzymelevelsto =2 times the normalvalue.Non-Q
wavemyocardialinfarction= absenceof newQ wavesdespite
this enzymeelevation.Eme~encyCABG = surgicalrevascu-
larizationperformedafter immediatetransferof the patient
from the cardiaccatheterizationlaboratoryto the operating
roomor within24h. ElectiveCABG = surgicalrevasculariza-









withflowimpairmentat the stentsite.RepeatPTCA = a new
percutaneousinterventionperformedfor the treatment of
stentrestenosisor of a newlesion.Vascularcomplications=




the stentingprocedure,duringthe hospitalstayor duringthe
follow-upperiod.
Proceduralsuccess= primarystentsuccesswithouttheneed
for emergencyCABGor emergencyPTCA and withoutthe
occurrenceof Q wavemyocardialinfarctionor death. Stent
restenosis= =50’%lumenreductionoccurringat the stentsite
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Follow-up.At the time of initialstent implantation,pa-
tients were informedabout the need for angiographicand
clinicalfollow-up.Beforedischarge,repeat angiographywas
scheduledfor each patient5 to 6 monthsafter stent implan-
tation. If follow-upangiographywas performedat another
institutionthe angiogramswere obtainedto permit perfor-
mance of quantitativeangiographicanalysis.If symptoms
recurredbeforethe scheduledfollow-upstudy,an angiogram




was collectedon dedicatedforms.For patientswho had a
clinicaleventsuchaselectiveCABG,myocardialinfarctionor
death,clinicalfollow-upendedat the timeof the event.If at
the timeofinterviewmultipleeventshadoccurred,allofthem




meanvaluet SD.Data that are not normallydistributedare
expressedasmedianandrangeofvalues.A two-tailedStudent
t test and analysesof single and multiplevariancewere
performedto testdifferencesamongcontinuousvariables.The
chi-squaretestwasusedto test categoricvariables.Predictors
of restenosiswere evaluatedby univariateand multivariate




Patient and angiographiccharacteristics.Therewere 128
consecutivepatientswitha mean age of 56 ~ 10years;9170
weremale.Thecompleteclinicalcharacteristicsare presented
in Table1.A totalof 139lesionswere treated.One previous
PTCA had been performedin 124patients(97%)and two
previousPTCASin 4. The mean timefromthe lastPTCAto
the occurrenceof restenosiswas 175t 154days.The angio-
graphicdistributionand characteristicsof the lesionstreated
are showninTable2.A totalof205stentswereimplanted;187
werePalmaz-Schatzstents.Othertypesofstentwereoccasion-
allyused in anatomicsettingsconsideredunfavorablefor the
Palmaz-Schatzstent. The short Palmaz-Schatzstent was
mainlyusedto treat a residuallesionnot completelycovered





126patients(98%).The successrate in the initial83patients
whounderwentstentimplantationwithoutIVUSguidancedid
not differfromthat in the subsequent42patientsundergoing


































Complications.Complicationsoccurred in four patients
(3.1%).One patient died after undergoingsuccessfulstent
implantationon an ostiallesionof the rightcoronaryartery



































criteria.Valuespresentedare number(%) of lesions.LAD= Left anterior
descendingcoronaryartery;I-Q = leftcicumflexcoronaryartery;RCA= right
coronaryartery.

















































emergencyCABG was performed in two patients:in one
becausecoronaryruptureoccurredduringstentoptimization
and in one becausea suboptimalpost-stentingangiographic
resultdid not appear suitablefor improvementwith current
transcathetertechniques.The patientwith corona~ rupture
had undergonestentdilationwitha balloon/arteryratioof 1.2
and use of a semicompliantballooninflatedat 12 atm. The
increasein balloonsizeafterthe increasein inflationpressure
mostprobablychangedthe balloon/arteryratio unfavorably.
Onepatientin the IVUSgrouphadsubacutestentthrombosis
on day 14after stent implantation.Thispatientwassuccess-




quantitativeangiographicdata are shownin Tables4 and 5.
ThedatainTable5 showthe resultsobtainedbeforeandafter
the utilizationof IVUS.The significantdifferencein the final
balloonpressurein the IVUS-guidedgroupreflectsthe typical
strategyof highpressurefinaldilationspecificallyemployed
with this approach.The IVUS variablesof the 50 lesions
undergoingIvUS-guidedstent implantationare shownin
Table5. Thesepatientssatisfiedthe criteriafor IVUS-guided
optimalstentexpansionpreviouslyreported(12,13).
.kgiographic restenosis and clinical follow-up.Angio-
graphicfollow-upwasobtaineda meanof6.6t 3monthsafter
theprocedurein 110(89%)of the 124patientswithsuccessful
stenting.ThemeanMLDat follow-upforalllesionsof 2.14f
0.97mmcorrespondedto a lossindexof 0.30t 0.46.Angio-
graphicrestenosisbased on 50% lumendiameternarrowing
















3.10t 0.57 3.1t 0.45 2.97? 0.53
0.79~ 0.36 3.14t 0.53 2.14~ 0.97












foundin a controlangiogramobtainedat 198* 135daysafter
the procedure,and the meanpercentstenosiswas73 ? 12Y0.
Of these 27 patientswith angiographicrestenosis,23 under-
went a newrevascularizationbecauseof symptomsor docu-
mented ischemia(15 new angioplastiesand 8 new CABG
operations);the otherpatientscontinuedon medicaltherapy
owingto absenceof demonstrableischemia.
Clinicalfollow-upwas availablein all 125patientswith
successfulstentingat a mean of 21 t 10months(range4 to
51).Lateeventsoccurredin23patients(19%)andincluded15
coronaryangioplasties,8 electiveCABGoperationsand2 late
deaths.No patienthad a myocardialinfarctionat follow-up.
The Kaplan-Meieractuarialsurvivalcurvesfor each cardiac
eventand for all eventsare shownin Figure1.The actuarial
survivalat 1 and 3 yearswas98’%oand the event-freesurvival
rate was95’?ZOat 1yearand subsequentlydeclinedto 76920.In
the 15 patientswho had repeat angioplastyto treat stent
restenosisclinicalfollow-upfindingsat 18 t 5 monthsindi-
catedthatall15remainedasymptomaticwithnofurtherevents




Anticoagulantregimens. Of the 128studypatients,42who
underwentstentinglater in the trial were treated onlywith
antiplateletsagents(ticlopidineand aspirin).These patients
treated withoutsubsequentanticoagulationwere part of an
ongoingstudyintendedto evaluateIWS-guidedstentimplan-
tation.Thepatientswhounderwentconventionallyperformed
stent implantationand those who had IWS-guided stent
implantationare comparedin Table 5. The onlydifferences
(bothexpected)betweenthesetwogroupsofpatientswerethe
lengthof hospitalstayand the durationof follow-upinterval.
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Table5. Quantitative AngiographicMeasurements, Procedural and
Follow-UrIData in the 121Patients With SuccessfulStentirw
lesionsite(proximal26%,mid18%,distal27%[p= NS])and
















The major findingof this study is that coronarystent
implantationto treat restenosisafterPTCAis associatedwith
an angiographicsecond restenosisrate of 2570 and very
favorablelong-termfollow-upfindings.Thisrate is lowerthan
those reported for other transcathetermethods(directional





stentingwithout routine high pressure final stent dilation,
withoutIVUSguidanceandwithsubsequentanticoagulation;
the subsequent42patientsweretreatedonlywithantiplatelet
agentsand undenventstentingwith both highpressurefinal
stent dilationand IVUS guidance.The initial 83 patients,
despite less aggressivedilationafter stenting,underwenta
rigorousangiographicoptimizationstrategyutilizingan aver-
age finalballoonsizeof 3.59 t 0.55mm,with a 1.1 t 0.14
balloon/angiographicreferencevesselratio and withachieve-
ment of a finalresidualstenosisof 5.3 t 10.85?ZO.The data
showthat the majoradvantageof the implantationstrategyin
the subsequent41patientswasa reductionin hospitalstay.It
followsthat the majorbenefitsof an aggressivepost-stenting




ageet al.(17).In thelatterstudya subacutethrombosisrate of
4.7%anda restenosisrate of 39%werefoundin patientswith
previousangioplasty.Anotherreport (18),usingWiktorstent
implantationto treat restenoticlesionsafter PTCA,founda
stent thrombosisrate of 159Z0and a restenosisrate of 3090.
Thesefindingsmayreflectthe shortcomingsof the traditional
techniquepreviouslyusedto performcoronarystenting.How-
ever,twohighvolumesinglecenters(19,20)reportedverylow
































































presentedare number(%)ofpatientsor meanvaluet SD.IWS = intravas-
cularultrasound;otherabbreviationsas inTable1.
foundin the incidenceof restenosisregardingarterylocation
(leftanteriordescendingcoronaryartery18%,rightcoronary
artery 37%, left circumflexcoronaryartery 13%[p = NS]);
1l“x- Death.9 Death+ CABG Figure1. The actuarial event-free survivalin the
study patients. The following events were in-
cluded: death, myocardial infarction, coronary
artery bypasssurgery (CABG) and repeat angio-
plasty of the stented restenotic lesion (new
PTCA). No patient had a myocardirdinfarction
during follow-up.
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Table6. Predictors of Restenosis





















































































































Vahrespresentedarenumber(%)ofpatientsormeanvalue~ SD;LV= Ieftventrietdar;Max= maximal;MLD= minimalumendiameter;post= afterstenting;
pre = beforestenting;Stand.Coeff.= standardcoefficient.




patient indicatesthe need to pay attentionto the balloon/
arteryratio, especiallywhenutilizingcompliantor semicom-
pliantballoons.
Role of IVUS. Becauseonly41patientsin our studywere
treated with IVUS-guidedstenting,we cannot draw firm
conclusionson the roleof IWS in the resultsachievedin this
small group. Multivariateanalysisdid not providespecific
informationconcerningthe role of clinicalor procedural
variablesin subsequentstent restenosis.One reasonmaybe
the smallgroupsize;however,it is possiblethat stentresten-
osiswasmainlycontrolledbyfactorsnot analyzedin thisstudy
in whichan optimalresultwas achievedin mostpatients.In
particular,the lack of associationbetween the final MLD
achievedand the risk of subsequentrestenosisseemsunex-
pected.A possibleexplanationfor thisnegativefindingis that
the techniqueused producedthe best possiblefinalMLDin
mostlesions.
Althoughour studydid not attempt to comparestenting
versusangioplastyin the treatmentof restenosis,somehistor-
ical“control”groupsmaybe analyzed.In thestudyofWilliams
et al. (21)in patientsin the NationalHeart,Lung,and Blood
InstitutePTCA registry,the restenosisrate after a second
PTCA was 34%. Another studyfrom Emory Universityof
1,490patientswho undenventPTCA for restenosisshowed
angiographicrestenosisin5190oflesions(22).A recentreview
articleof Levineat al. (23)combiningdata fromeightpubli-
cationsreported a restenosisrate of 4070after angioplasty
performedfor a thirdor fourthrestenosis.
From the clinicalpoint of viewit is positivethat the 15
patients in our study who had stent restenosisand who
underwentsubsequentPTCAhavebeenfree of clinicalrecur-
rence at a mean follow-upintervalof 8 months.It is also
interestingthat sixpatientswho met the criteria for angio-
graphicrestenosiswere free of inducibleischemia,did not
requireinvasivetreatmentand had an uneventfulfollow-up.
These findingssupport the conclusionthat 60% to 70%
angiographicstentnarrowingis frequentlynot clinicallyrele-
vant (24).
Conclusions. Consideringthese findings,we believethat
coronarystentingcan be safelyused to treat restenosisafter
PTCA.The angiographicrestenosisrate of 25%andthe short
hospitalstayassociatedwith a better implantationtechnique
are likelyto makestentinga cost-effectiveprocedurefor this
specificindication(25).Theroleof IWS in the grouptreated
withfinalhighpressureinflationand no anticoagulationwas
not specificallyexamined.However,it is likelythat routine
highpressurestentimplantationassociatedwithangiographic
optimizationwillyieldcomparableresults.
Limitationsof the study. Thisretrospectiveobservational
studyprovideslong-termfollow-upresultsfroma singlecenter.
The studywasnot designedto comparestentingfor restenosis
withother treatmentmodalities.The resultsof ongoingran-
domizedstudiessuch as the REST trial (26) may further
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